{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:54Z","timestamp":1785560274921,"version":"3.56.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.2169\/internalmedicine.6396-25","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:08:06Z","timestamp":1765404486000},"page":"2058-2067","source":"Crossref","is-referenced-by-count":1,"title":["A Retrospective Study of the Efficacy and Safety of Epcoritamab in Real-world Clinical Practice: An Analysis of 19 Cases from a Single Institution"],"prefix":"10.2169","volume":"65","author":[{"given":"Yasunobu","family":"Sekiguchi","sequence":"first","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Maseki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Iizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"},{"name":"Department of Clinical Laboratory Medicine, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Inspection Engineering, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kakusaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Shimano","sequence":"additional","affiliation":[{"name":"Department of Radiation Therapy, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Takahata A, Shimada T, Bando K, Toyota S. Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review. Ann Hematol 104: 1995-2000, 2025.","DOI":"10.1007\/s00277-025-06206-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Imataki O, Uemura M, Fujita H, Kadowaki N. Pathological landscape of tumor flare reaction to epcoritamab treatment. Int J Hematol 120: 467-471, 2024.","DOI":"10.1007\/s12185-024-03833-w"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takahata A, Akita K, Shimada T, Bando K, Toyota S. Utility of CSF IL-6 monitoring in managing ICANS associated with Epcoritamab treatment: a case report and literature review. J Clin Exp Hematop 65: 68-71, 2025.","DOI":"10.3960\/jslrt.24080"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sekiguchi Y, Tsutsumi H, Kudo M, et al. Treatment with epcoritamab in 10 patients in real-world clinical practice. J Clin Exp Hematop 64: 332-334, 2024.","DOI":"10.3960\/jslrt.24054"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3068, 2014.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Thieblemont C, Karimi YH, Ghesquieres H, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38: 2653-2662, 2024.","DOI":"10.1038\/s41375-024-02410-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Izutsu K, Kumode T, Yuda J, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci 114: 4643-4653, 2023.","DOI":"10.1111\/cas.15996"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Izutsu K, Kumode T, Yuda J, et al. Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial. Int J Clin Oncol 30: 1631-1640, 2025.","DOI":"10.1007\/s10147-025-02788-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J 11: 38, 2021.","DOI":"10.1038\/s41408-021-00430-6"},{"key":"11","unstructured":"11. Zhang J, Wielgos-Bonvallet M, Si H, et al. Immune correlates of response to epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma: dose expansion in a phase 1\/2 trial. EHA P1244, 2024."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Brooks TR, Zabor EC, Bedelu YB, et al. Real-world outcomes with bispecic T-cell engagers (REALBiTE) for relapsed or refractory large B-cell lymphoma: a multi-center, retrospective cohort study. Blood 144 (Supplement 1): 111, 2024.","DOI":"10.1182\/blood-2024-199330"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hayashi K, Nagasaki E, Kan S, et al. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer Sci 107: 682-689, 2016.","DOI":"10.1111\/cas.12918"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawasaki N, Nishito Y, Yoshimura Y, Yoshiura S. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol 199: 245-255, 2022.","DOI":"10.1111\/bjh.18341"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lyu L, Yi M, Chen J, et al. Bispecific antibody targeting VEGF\/TGF-\u03b2 synergizes with local radiotherapy: turning tumors from cold to inflamed and amplifying abscopal effects. Adv Sci (Weinh) 12: e01819, 2025.","DOI":"10.1002\/advs.202501819"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Phillips T, Clausen M, Jurczak W, et al. Prior bendamustine exposure did not impact clinical outcomes and decreased CD4+ but not CD8+ T cells in patients with diffuse large B-cell lymphoma treated with the bispecific antibody epcoritamab. ASH 3115, 2024.","DOI":"10.1182\/blood-2024-199799"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ljungman P, Alain S, Chemaly RF, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis 25: e451-e462, 2025.","DOI":"10.1016\/S1473-3099(25)00069-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Braun A, Gouni S, Pulles A, Strati P, Minnema MC, Budde LE. Bispecific antibody use in patients with lymphoma and multiple myeloma. Am Soc Clin Oncol Educ Book 44: e433516, 2024.","DOI":"10.1200\/EDBK_433516"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6396-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:13:47Z","timestamp":1785557627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6396-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6396-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"6396-25"}}